UK Markets close in 1 hr 21 mins

Newron Pharmaceuticals S.p.A. (NWPHF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
2.10000.0000 (0.00%)
As of 02:18PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close2.1000
Open2.1000
Bid0.0000 x 0
Ask0.0000 x 0
Day's range2.1000 - 2.1000
52-week range2.1000 - 3.0000
Volume2,000
Avg. volume31
Market cap37.475M
Beta (5Y monthly)0.96
PE ratio (TTM)N/A
EPS (TTM)-1.2390
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • EQS Group

    Change in Newron Board of Directors

    Newron Pharmaceuticals SpA / Key word(s): Personnel01-Dec-2021 / 17:46 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LRMilan, Italy - Dec. 1, 2021 - Newron Pharmaceuticals S.p.A. ('Newron', SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today annou

  • EQS Group

    Newron Receives Fifth Tranche from Financing Agreement with European Investment Bank (EIB)

    Newron Pharmaceuticals SpA / Key word(s): Financing18-Oct-2021 / 17:45 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 SIX Listing RulesMilan, Italy - October 18, 2021, 5:45 pm CEST - Newron Pharmaceuticals S.p.A. ('Newron') (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peri

  • Business Wire

    Newron Announces Half-Year 2021 Results

    MILAN, September 16, 2021--Newron Pharmaceuticals S.p.A. (SIX: NWRN, XETRA: NP5) today announces its operational and financial results for the half-year ended June 30, 2021.